Claims
- 1. A composition comprising
a Hoogsteen binding arm that binds by Hoogsteen base pairing to a target nucleic acid molecule at a first target site, and a Watson-Crick binding arm that binds by Watson-Crick base pairing to the target nucleic acid molecule at a second target site, wherein the Hoogsteen binding arm and the Watson-Crick binding arm are conjugated to each other, and are comprised of nucleic acid or nucleic acid mimic elements.
- 2. The composition of claim 1, wherein the Hoogsteen binding arm is selected from the group consisting of a DNA, an RNA, a PNA, and an LNA.
- 3. The composition of claim 1, wherein the Watson-Crick binding arm is selected from the group consisting of a DNA, an RNA, a PNA, and an LNA.
- 4. The composition of claim 1, wherein the target nucleic acid molecule is a DNA or an RNA.
- 5. The composition of claim 1, wherein the Hoogsteen binding arm has at least one backbone modification.
- 6. The composition of claim 1, wherein the Watson-Crick binding arm has at least one backbone modification.
- 7. The composition of claim 5 or 6, wherein the at least one backbone modification is selected from the group consisting of a peptide modification, and a phosphorothioate modification.
- 8. The composition of claim 1, wherein the Hoogsteen binding arm and the Watson-Crick binding arm are conjugated to each other covalently.
- 9. The composition of claim 1, wherein the Hoogsteen binding arm and the Watson-Crick binding arm are conjugated to each other using a linker molecule.
- 10. The composition of claim 9, wherein the linker molecule is selected from the group consisting of 8-amino-3,6-dioxaoctanoic acid (O-linker), E-linker, and X-linker.
- 11. The composition of claim 9, wherein the linker molecule comprises a cleavable bond.
- 12. The composition of claim 9, wherein the linker molecule has a length of less than 100 Angstroms.
- 13. The composition of claim 1, wherein the Hoogsteen binding arm has a nucleotide sequence that is a homopurine nucleotide sequence or homopyrimidine nucleotide sequence.
- 14. The composition of claim 1, wherein the Watson-Crick binding arm has a nucleotide sequence that is random.
- 15. The composition of claim 1, wherein the Hoogsteen binding arm is 5-12 nucleotides in length.
- 16. The composition of claim 1, wherein the Watson-Crick binding arm is 5-12 nucleotides in length.
- 17. The composition of claim 1, wherein the Hoogsteen binding arm and the Watson-Crick binding arm have different lengths.
- 18. The composition of claim 1; wherein the first target site and the second target site are spaced apart from each other by a distance selected from the group consisting of 1 base pair, 2 base pairs, 5 base pairs, 7 base pairs, 10 base pairs, 20 base pairs, and 25 base pairs.
- 19. The composition of claim 1, wherein the Hoogsteen binding arm and the Watson-Crick binding arm, when both are bound to their respective target sites, are spaced apart from each other by a distance selected from the group consisting of 1 base pair, 2 base pairs, 5 base pairs, 7 base pairs, 10 base pairs, 20 base pairs, and 25 base pairs.
- 20. The composition of claim 1, wherein the Hoogsteen binding arm is conjugated to an agent.
- 21. The composition of claim 1 or 20, wherein the Watson-Crick binding arm is conjugated to an agent.
- 22. The composition of claim 20 or 21, wherein the agent is a detectable label.
- 23. The composition of claim 22, wherein the detectable label is selected from the group consisting of an electron spin resonance molecule (e.g., nitroxyl radicals), a fluorescent molecule, a chemiluminescent molecule, a radioisotope, an enzyme substrate, a biotin molecule, an avidin molecule, an electrical charge transferring molecule, a semiconductor nanocrystal, a semiconductor nanoparticle, a colloid gold nanocrystal, a ligand, a microbead, a magnetic bead, a paramagnetic particle, a quantum dot, a chromogenic substrate, an affinity molecule, a protein, a peptide, a nucleic acid, a carbohydrate, an antigen, a hapten, an antibody, an antibody fragment, and a lipid.
- 24. The composition of claim 22, wherein the detectable label is detected using a detection system selected from the group consisting of a charge coupled device detection system, an electron spin resonance detection system, a fluorescent detection system, an electrical detection system, a photographic film detection system, a chemiluminescent detection system, an enzyme detection system, an atomic force microscopy (AFM) detection system, a scanning tunneling microscopy (STM) detection system, an optical detection system, a nuclear magnetic resonance (NMR) detection system, a near field detection system, and a total internal reflection (TIR) detection system.
- 25. The composition of claim 20 or 21, wherein the agent is a cytotoxic agent.
- 26. The composition of claim 1, wherein the target nucleic acid molecule is a genomic DNA molecule or a mitochondrial DNA molecule.
- 27. A composition comprising
a Hoogsteen binding arm that binds by Hoogsteen base pairing to a target nucleic acid molecule at a first target site, and a Watson-Crick binding arm that binds by Watson-Crick base pairing to the target nucleic acid molecule at a second target site wherein the Hoogsteen binding arm and the Watson-Crick binding arm are conjugated to each other through a linker.
- 28. A method for labeling a target nucleic acid molecule comprising
a) contacting the target nucleic acid molecule with a composition of claim 1 or 27, and b) allowing the composition to bind specifically to the target nucleic acid molecule.
- 29. The method of claim 28, further comprising detecting binding of the composition to the target nucleic acid molecule.
- 30. The method of claim 28, wherein the Hoogsteen binding arm is selected from the group consisting of a DNA, an RNA, a PNA, and an LNA.
- 31. The method of claim 28, wherein the Watson-Crick binding arm is selected from the group consisting of a DNA, an RNA, a PNA, and an LNA.
- 32. The method of claim 28, wherein the Hoogsteen binding arm has at least one backbone modification.
- 33. The method of claim 28, wherein the Watson-Crick binding arm has at least one backbone modification.
- 34. The method of claim 32 or 33, wherein the at least one backbone modification is selected from the group consisting of a peptide modification and a phosphorothioate modification.
- 35. The method of claim 28, wherein the Hoogsteen binding arm and Hoogsteen binding arm are conjugated to each other covalently.
- 36. The method of claim 28, wherein the Hoogsteen binding arm and Hoogsteen binding arm are conjugated to each other using a linker molecule.
- 37. The method of claim 36, wherein the linker molecule is selected from the group consisting of 8-amino-3,6-dioxaoctanoic acid (O-linker), E-linker, and X-linker.
- 38. The method of claim 36, wherein the linker molecule comprises a hydrolyzable cleavable.
- 39. The method of claim 36, wherein the linker molecule has a length of less than 100 Angstroms.
- 40. The method of claim 28, wherein the Hoogsteen binding arm has a nucleotide sequence that is a homopurine nucleotide sequence or homopyrimidine nucleotide sequence.
- 41. The method of claim 28, wherein the Watson-Crick binding arm has a nucleotide sequence that is random.
- 42. The method of claim 28, wherein the Hoogsteen binding arm is 5-12 nucleotides in length.
- 43. The method of claim 28, wherein the Watson-Crick binding arm is 5-12 nucleotides in length.
- 44. The method of claim 28, wherein the Hoogsteen binding arm and the Watson-Crick binding arm have different lengths.
- 45. The method of claim 28, wherein the first target site and the second target site are spaced apart from each other by a distance selected from the group consisting of 1 base pair, 2 base pairs, 5 base pairs, 7 base pairs, 10 base pairs, 20 base pairs, and 25 base pairs.
- 46. The method of claim 28, wherein the Hoogsteen binding arm and the Watson-Crick binding arm, when both are bound to their respective target sites, are spaced apart from each other by a distance selected from the group consisting of 1 base pair, 2 base pairs, 5 base pairs, 7 base pairs, 10 base pairs, 20 base pairs, and 25 base pairs.
- 47. The method of claim 28, wherein the Hoogsteen binding arm is conjugated to an agent.
- 48. The method of claim 28 or 47, wherein the Watson-Crick binding arm is conjugated to an agent.
- 49. The method of claim 47 or 48, wherein the agent is a detectable label.
- 50. The method of claim 49, wherein the detectable label is selected from the group consisting of an electron spin resonance molecule (e.g., nitroxyl radicals), a fluorescent molecule, a chemiluminescent molecule, a radioisotope, an enzyme substrate, a biotin molecule, an avidin molecule, an electrical charge transferring molecule, a semiconductor nanocrystal, a semiconductor nanoparticle, a colloid gold nanocrystal, a ligand, a microbead, a magnetic bead, a paramagnetic particle, a quantum dot, a chromogenic substrate, an affinity molecule, a protein, a peptide, a nucleic acid, a carbohydrate, an antigen, a hapten, an antibody, an antibody fragment, and a lipid.
- 51. The method of claim 49, wherein the detectable label is detected using a detection system selected from the group consisting of a charge coupled device detection system, an electron spin resonance detection system, a fluorescent detection system, an electrical detection system, a photographic film detection system, a chemiluminescent detection system, an enzyme detection system, an atomic force microscopy (AFM) detection system, a scanning tunneling microscopy (STM) detection system, an optical detection system, a nuclear magnetic resonance (NMR) detection system, a near field detection system, and a total internal reflection (TIR) detection system.
- 52. The method of claim 47 or 48, wherein the agent is a cytotoxic agent.
- 53. The method of claim 48, wherein the agent is a nucleic acid cleaving agent.
- 54. The method of claim 28, wherein the target nucleic acid molecule is a DNA or an RNA molecule.
- 55. The method of claim 28, wherein the target nucleic acid molecule is a genomic DNA molecule or a mitochondrial DNA molecule.
- 56. The method of claim 29, further comprising determining a pattern of binding of the composition to the target nucleic acid molecule.
- 57. The method of claim 56, wherein the pattern of binding is determined using a linear polymer analysis system, FISH, or optical mapping.
- 58. The method of claim 56, wherein the pattern of binding is determined by detecting and measuring cleavage products from the target nucleic acid molecule.
- 59. The method of claim 56, wherein the pattern of binding is indicative of a loss of transcription.
- 60. The composition of claim 1, wherein the Hoogsteen binding arm comprises a PNA.
- 61. The composition of claim 1 or claim 60, wherein the Watson-Crick binding arm comprises a PNA.
- 62. The method of claim 28, wherein the Hoogsteen binding arm comprises a PNA.
- 63. The method of claim 28, wherein the Watson-Crick binding arm comprises a PNA.
RELATED APPLICATIONS
[0001] This application claims priority to U.S. Provisional Patent Application filed Apr. 23, 2002, entitled “NOVEL TWO-ARM PNA DESIGN FOR EXPANDED TARGETING OF DNA MOTIFS USING WATSON-CRICK AND HOOGSTEEN BINDING STRANDS BINDING TO DIFFERENT PORTIONS OF THE MOTIF”, Serial No. 60/374,749, the contents of which are incorporated by reference herein in their entirety.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60374749 |
Apr 2002 |
US |